# Cell and Gene Therapy for Neurodevelopmental Disorders Conference

> **NIH NIH R13** · UNIVERSITY OF CALIFORNIA AT DAVIS · 2021 · $10,000

## Abstract

Gene therapy via infusion of engineered viral vector or gene-modified cells has the potential to
permanently change the health of a patient, potentially sparing them from a lifetime of battling
their disease. Although the field of gene therapy is not new, a robust expansion of efforts stoked
by the successes of immunotherapy and commercialization of the first products is now
occurring. The 2021 conference “Cell and Gene Therapy for Neurodevelopmental Disorders” is
an early discussion of how to develop safe and effective treatments for children suffering from
neurodevelopmental disorders caused by single – gene defects. New advances in this field are
actively studied by the expert speakers for this conference, who are all working on cutting-edge
research that has the goal of providing future treatments. The conference is strongly focused on
evidence-based science, and an ethics speaker will inform attendees about the risks of false
promises from the unregulated “stem cell clinics”. This R13 application seeks funding to support
travel awards for graduate or medical students and postdoctoral fellows to attend the
conference. At least half of the awards will be reserved for students from traditionally under-
represented minority groups. To facilitate trainee interaction with the keynote speakers, the
conference will be limited to 150 participants and will feature a trainee/speaker dinner and a
trainee lunch workshop, short talks from the travel award winners, and ample opportunity for
networking. We are also offering an affordable “virtual attendance” option to broaden the
audience. There is a session on “Diversity and International Collaboration” and a panel on
“Parent and Patient Advocacy,” with diverse speakers. In bringing novel cell and gene therapy
trials from bench to bedside and into routine clinical practice, many scientists, MDs, healthcare,
regulatory, manufacturing and other staff members work together in large teams, in consultation
with parents and patient advocates. Developing this integrated teamwork to enhance therapy for
neurodevelopmental disorders is a central theme of the conference.

## Key facts

- **NIH application ID:** 10237084
- **Project number:** 1R13NS117001-01A1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA AT DAVIS
- **Principal Investigator:** RANDI J. HAGERMAN
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $10,000
- **Award type:** 1
- **Project period:** 2021-09-15 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10237084

## Citation

> US National Institutes of Health, RePORTER application 10237084, Cell and Gene Therapy for Neurodevelopmental Disorders Conference (1R13NS117001-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10237084. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*